An independent research digest on the GLOW peptide blend — GHK-Cu, BPC-157, and TB-500, read through the literature.
GLOW Telehealth

GLOW Peptide Dosage in the Research Literature

GLOW Peptide Dosage in the Research Literature

GLOW peptide dosage data does not exist for the combined blend. No human dose-ranging study for GHK-Cu + BPC-157 + TB-500 as a combined formulation has been published. All dosage information on this page derives from studies of individual constituents in animal models or human clinical trials.

The three constituents were studied across substantially different dose units, routes, species, and endpoints. Collapsing them into a single human dose recommendation would be scientifically unjustified. This page organizes the studied dose ranges for each constituent as reported in primary literature, with species and route context.

Studied Doses of GLOW Peptide Constituents

GHK-Cu studied doses:

  • In vitro (collagen stimulation, human fibroblasts): 10⁻¹² to 10⁻⁹ M range [1]
  • In vitro (stem cell markers, wound healing): 0.1-10 micromolar [3]
  • Rodent (bone fracture healing): 2.2 mcg/kg systemic [3]
  • Rodent (pulmonary fibrosis suppression, C57BL/6 mice): 2.6, 26, and 260 mcg/mL/day alternating days IP on days 4-21 post-bleomycin induction [4]
  • Rodent (cognitive aging, intranasal): 15 mg/kg daily via 3D-printed atomizer in 20-month-old mice [21]
  • Human clinical (topical skin): undisclosed concentrations twice daily for 12 weeks in two published trials [23]
  • Human clinical (topical hair growth): 50 mg/mL and 100 mg/mL topical ALAVAX formulation; statistically significant hair count at 6 months [5]

No published human injectable pharmacokinetic study for GHK-Cu exists.

BPC-157 studied doses:

  • Rodent (wound healing, burn models): 10 mcg/kg, 10 ng/kg, 10 pg/kg IP; per-oral (drinking water); topical cream 1 mcg/g [8]
  • Rodent (tendon fibroblast GHR upregulation): 0.1-0.5 mcg/mL cell culture [9]
  • Rodent (quadriceps reattachment): 10 mcg/kg, 10 ng/kg per-oral [10]
  • Rodent (anastomosis): 10 mcg/kg, 10 ng/kg IP or oral once daily [11]
  • Pharmacokinetic study (rats and dogs): IV 20-500 mcg/kg, IM 6-500 mcg/kg [14]
  • Human pilots: specific doses not published in available abstracts [13]

TB-500 studied doses:

  • Rodent (dystrophic muscle regeneration): 150 mcg twice weekly x 6 months IP [19]
  • Rodent (skin flap survival): 5 mg/kg twice daily systemic [17]
  • Human Phase I (healthy volunteers, thymosin beta-4): IV 0.05-25.0 mcg/kg single dose and multiple doses over 10 days [18]
  • Human Phase II (dry eye, topical): 2 mg/mL eye drops [17]
  • Human wound trial: 0.01-0.1% topical gel for 84 days [17]

GLOW Peptide Protocol: Cycling and Administration Notes

How long should you stay on GLOW peptide? Published literature does not specify a human cycle length for the combined blend. Cycling patterns in the constituent research: BPC-157 rodent studies ran 4-12 weeks continuous without published toxicity signals at studied doses; TB-500 dystrophic mouse studies used 6-month continuous IP dosing without toxicity findings [19]. No combined-blend cycling randomized controlled trial exists.

How do you cycle GLOW peptide? Cycling data is drawn from constituent studies: BPC-157 rodent studies ran 4-12 weeks continuous; TB-500 studies used shorter burst cycles in some models. No combined-blend cycling RCT exists as of 2026.

How long can you take GLOW peptide? Long-term safety data for the GLOW blend in humans is absent from peer-reviewed literature. Individual constituent studies in rodents ran 4-12 weeks (BPC-157) and up to 6 months (TB-500) without published toxicity signals at studied doses [8][19].

How long does it take for GLOW peptide to start working? Preclinical data suggest GHK-Cu effects on collagen markers appear within days in cell culture [1]; observable tissue outcomes in rodent wound models emerge over 1-4 weeks depending on endpoint [10].

GLOW Peptide Injection: Reconstitution and Administration in Research

How do you reconstitute GLOW peptide? Research vials are typically reconstituted with bacteriostatic water (BAC water) — sterile water containing 0.9% benzyl alcohol for multi-use vial stability. Standard bench protocols for the 70 mg GLOW 70 format use 3 mL BAC water per vial, yielding approximately 23 mg/mL total peptide concentration across the three constituents. Actual reconstitution calculation depends on vial-specific peptide mass.

Reconstitution: BAC Water Volume for GLOW Peptide. The 3 mL BAC water standard for 70 mg vials is a bench convention, not a published clinical protocol. Individual constituent vial concentrations vary by supplier and formulation. The reconstitution calculation is: (vial mass in mg) ÷ (BAC water volume in mL) = mg/mL concentration.

Where to Inject GLOW Peptide: Administration Routes in Studies. Rodent studies for BPC-157 and TB-500 primarily used subcutaneous or intraperitoneal injection; GHK-Cu research includes both topical and subcutaneous routes [3][14]. Human injection sites are not validated in published clinical trials for any of the three GLOW constituents.

How Often Should You Inject GLOW Peptide? In rodent models, BPC-157 was typically dosed daily [8]; TB-500 studies used less frequent protocols — twice weekly in the 6-month dystrophic mouse study [19]. No combined-blend frequency data exists in the published literature.

GLOW Peptide Dosing: What the Research Literature Shows. Preclinical dosing varies by model, species, and endpoint. BPC-157 achieved equipotent effects across doses spanning four orders of magnitude (10 mcg/kg to 10 pg/kg) in burn models [8], indicating broad dose-response. TB-500 was studied at doses from 0.05 mcg/kg (human Phase I IV) to 5 mg/kg twice daily in skin flap rodent models — a range that reflects the difficulty of cross-species dose translation [17][18]. For the reconstitution and injection guide, see the section above.